Muse bio Finds $23M For Gene Editing Technology
Boulder-based Muse bio, a company developing gene editing technology, said on Tuesday that it has raised $23M in a Series B financing round. The funding was led by Venrock, and also included Foresite Capital, Paladin Capital, NanoDimension, and Spruce/MLS. The company said the funds will go to advance development of its gene editing and single-cell writing technology. Kevin Ness is CEO of Muse bio.
posted on Wednesday, March 1, 2017 (Link to more information)
Related companies:
Muse Biotechnology, Inc.
Related stories:
> Inscripta Finds $55.5M For Gene Editing Tools
> Inscripta Adds $20M To Series C Funding
> NewsGator Upgrades Weblog Editing Tool
> Pixorial Signs Online Film School
> CTRL+Console Gets $261K To Bring Pro Video Editing To The iPad
Techrockies.com Home